245 related articles for article (PubMed ID: 22192540)
1. Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization.
Wu Y; Wei W; Zhou M; Wang Y; Wu J; Ma G; Su Z
Biomaterials; 2012 Mar; 33(7):2351-60. PubMed ID: 22192540
[TBL] [Abstract][Full Text] [Related]
2. Novel thermal-sensitive hydrogel enhances both humoral and cell-mediated immune responses by intranasal vaccine delivery.
Wu Y; Wu S; Hou L; Wei W; Zhou M; Su Z; Wu J; Chen W; Ma G
Eur J Pharm Biopharm; 2012 Aug; 81(3):486-97. PubMed ID: 22507968
[TBL] [Abstract][Full Text] [Related]
3. Hydroxypropyltrimethyl ammonium chloride chitosan-based hydrogel as the split H5N1 mucosal adjuvant: Structure-activity relationship.
Fan Q; Miao C; Huang Y; Yue H; Wu A; Wu J; Wu J; Ma G
Carbohydr Polym; 2021 Aug; 266():118139. PubMed ID: 34044953
[TBL] [Abstract][Full Text] [Related]
4. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
5. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
7. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice.
Madhun AS; Haaheim LR; Nøstbakken JK; Ebensen T; Chichester J; Yusibov V; Guzman CA; Cox RJ
Vaccine; 2011 Jul; 29(31):4973-82. PubMed ID: 21600260
[TBL] [Abstract][Full Text] [Related]
8. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
9. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
[TBL] [Abstract][Full Text] [Related]
10. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Fang F; Zheng M; Chen Z
Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
[TBL] [Abstract][Full Text] [Related]
11. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
12. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H
Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660
[TBL] [Abstract][Full Text] [Related]
13. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
Ainai A; van Riet E; Ito R; Ikeda K; Senchi K; Suzuki T; Tamura SI; Asanuma H; Odagiri T; Tashiro M; Kurata T; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
Microbiol Immunol; 2020 Apr; 64(4):313-325. PubMed ID: 31957054
[TBL] [Abstract][Full Text] [Related]
14. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
[TBL] [Abstract][Full Text] [Related]
15. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
16. Sialivac: an intranasal homologous inactivated split virus vaccine containing bacterial sialidase for the control of avian influenza in poultry.
Worrall EE; Sudarisman ; Priadi A
Vaccine; 2009 Jun; 27(31):4161-8. PubMed ID: 19406183
[TBL] [Abstract][Full Text] [Related]
17. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.
Park KS; Lee J; Ahn SS; Byun YH; Seong BL; Baek YH; Song MS; Choi YK; Na YJ; Hwang I; Sung YC; Lee CG
Virology; 2009 Dec; 395(2):182-9. PubMed ID: 19836045
[TBL] [Abstract][Full Text] [Related]
18. A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.
Svindland SC; Pedersen GK; Pathirana RD; Bredholt G; Nøstbakken JK; Jul-Larsen Å; Guzmán CA; Montomoli E; Lapini G; Piccirella S; Jabbal-Gill I; Hinchcliffe M; Cox RJ
Influenza Other Respir Viruses; 2013 Nov; 7(6):1181-93. PubMed ID: 23170900
[TBL] [Abstract][Full Text] [Related]
19. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus.
Ichinohe T; Ainai A; Ami Y; Nagata N; Iwata N; Kawaguchi A; Suzaki Y; Odagiri T; Tashiro M; Takahashi H; Strayer DR; Carter WA; Chiba J; Tamura S; Sata T; Kurata T; Hasegawa H
J Med Virol; 2010 Oct; 82(10):1754-61. PubMed ID: 20827774
[TBL] [Abstract][Full Text] [Related]
20. Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine.
Hagenaars N; Mania M; de Jong P; Que I; Nieuwland R; Slütter B; Glansbeek H; Heldens J; van den Bosch H; Löwik C; Kaijzel E; Mastrobattista E; Jiskoot W
J Control Release; 2010 May; 144(1):17-24. PubMed ID: 20100528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
